Terns Pharmaceuticals, Inc.
TERN
Rank in Stocks
#3585
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Share Price
$52.95
Last synced: 2026-05-15
Market Cap
$4.77B
Change (1 day)
0.00%
Change (1 year)
529.61%
Country
US
Trade Terns Pharmaceuticals, Inc. (TERN)
Category
Healthcare
Earnings for Terns Pharmaceuticals, Inc. (TERN)
Earnings in Dec 2025 TTM: $-95.63M
According to Terns Pharmaceuticals, Inc. latest financial reports the company's current earnings are $-95.63M. In 2023 the company made an earning of $-89.97M, a decrease compared to its 2022 earnings that were of $-59.99M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Terns Pharmaceuticals, Inc. from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-95.63M | 7.94% |
| 2024 | $-88.59M | -1.53% |
| 2023 | $-89.97M | 49.98% |
| 2022 | $-59.99M | 20.82% |
| 2021 | $-49.65M | 70.87% |
| 2020 | $-29.06M | -57.79% |
| 2019 | $-68.84M | 280.64% |
| 2018 | $-18.09M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -5,616.18% |
US
|
|
| $-3.09B | 3,128.20% |
US
|
|
| $-4.02B | 4,099.90% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,139.87% |
NL
|
